Skip to content
Home/Companies/Biotech/Morphic Therapeutic

Morphic Therapeutic

Biotech·United States·Exited 2024·Held 1yr
Entry
2023
Hold
1yr
Exit
2024

Who owns Morphic Therapeutic?

Morphic Therapeutic is an American Biotech company, now owned by Eli Lilly, which acquired it in 2024 from Novo Holdings.

Hand-verified · updated 2026-08-18

Open JSON · CC-BY
Novo Holdings
Investor
Novo Holdings
Novo Holdings Venture Investments · 1999 · VC

Key facts

HQUnited States
SectorBiotech
StatusAcquired
Exit Type
Trade Sale
Buyer
Eli Lilly
Exit Year
2024

More from Novo Holdings Venture Investments

Other portfolio companies in the same fund.

Claris Biotherapeutics
Active
BiotechUS· 2026
Windward Bio AG
Active
BiotechSwitzerland· 2026
AnaCardio
Active
BiotechSweden· 2025
Expedition Therapeutics
Active
BiotechUS· 2025
KIVU Bioscience
Active
BiotechUS· 2025
Asceneuron
Active
BiotechSwitzerland· 2024

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Morphic Therapeutic?

Morphic Therapeutic is now owned by Eli Lilly, which acquired it in 2024 from Novo Holdings.

When did Eli Lilly acquire Morphic Therapeutic?

Eli Lilly acquired Morphic Therapeutic in 2024, buying from Novo Holdings.

Who did Morphic Therapeutic sell to?

Novo Holdings sold Morphic Therapeutic to Eli Lilly in 2024 (Trade Sale).

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue